000 | 01943 a2200493 4500 | ||
---|---|---|---|
005 | 20250515172035.0 | ||
264 | 0 | _c20090608 | |
008 | 200906s 0 0 eng d | ||
022 | _a1750-2659 | ||
024 | 7 |
_a10.1111/j.1750-2659.2008.00064.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aRudenko, Larisa | |
245 | 0 | 0 |
_aSafety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). _h[electronic resource] |
260 |
_bInfluenza and other respiratory viruses _cNov 2008 |
||
300 |
_a203-9 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdministration, Intranasal |
650 | 0 | 4 |
_aAntibodies, Viral _xblood |
650 | 0 | 4 | _aCross Reactions |
650 | 0 | 4 | _aHemagglutination Inhibition Tests |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunization, Secondary |
650 | 0 | 4 |
_aImmunoglobulin A _xanalysis |
650 | 0 | 4 |
_aInfluenza A Virus, H2N2 Subtype _xgenetics |
650 | 0 | 4 |
_aInfluenza A Virus, H5N1 Subtype _ximmunology |
650 | 0 | 4 |
_aInfluenza A Virus, H5N2 Subtype _xgenetics |
650 | 0 | 4 |
_aInfluenza Vaccines _xadministration & dosage |
650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
650 | 0 | 4 |
_aNasal Mucosa _ximmunology |
650 | 0 | 4 | _aNeutralization Tests |
650 | 0 | 4 |
_aReassortant Viruses _xgenetics |
650 | 0 | 4 | _aRussia |
650 | 0 | 4 |
_aVaccines, Attenuated _xadministration & dosage |
700 | 1 | _aDesheva, Julia | |
700 | 1 | _aKorovkin, Sergey | |
700 | 1 | _aMironov, Alexander | |
700 | 1 | _aRekstin, Andrey | |
700 | 1 | _aGrigorieva, Elena | |
700 | 1 | _aDonina, Svetlana | |
700 | 1 | _aGambaryan, Alexandra | |
700 | 1 | _aKatlinsky, Anton | |
773 | 0 |
_tInfluenza and other respiratory viruses _gvol. 2 _gno. 6 _gp. 203-9 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1750-2659.2008.00064.x _zAvailable from publisher's website |
999 |
_c18880265 _d18880265 |